KDR and neoplasm: Tumor cells can drive the migration of VEGFR2 expressing CEPs from the bone marrow to the tumor microenvironment through the production of VEGF and anti-VEGF/VEGFR therapy has been shown to decrease survival signaling and mobilization of CEPs to the site of tumor growth [17–20].